TW200942549A - Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 - Google Patents
Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1Info
- Publication number
- TW200942549A TW200942549A TW097148847A TW97148847A TW200942549A TW 200942549 A TW200942549 A TW 200942549A TW 097148847 A TW097148847 A TW 097148847A TW 97148847 A TW97148847 A TW 97148847A TW 200942549 A TW200942549 A TW 200942549A
- Authority
- TW
- Taiwan
- Prior art keywords
- imidazolo
- oxazolo
- trpv1
- thiazolopyrimidine
- modulators
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/4965—Non-condensed pyrazines
- A61K31/497—Non-condensed pyrazines containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/10—Expectorants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/14—Antitussive agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/16—Otologicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/16—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 two nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/18—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one oxygen and one nitrogen atom, e.g. guanine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/02—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6
- C07D473/24—Heterocyclic compounds containing purine ring systems with oxygen, sulphur, or nitrogen atoms directly attached in positions 2 and 6 one nitrogen and one sulfur atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D473/00—Heterocyclic compounds containing purine ring systems
- C07D473/26—Heterocyclic compounds containing purine ring systems with an oxygen, sulphur, or nitrogen atom directly attached in position 2 or 6, but not in both
- C07D473/32—Nitrogen atom
- C07D473/34—Nitrogen atom attached in position 6, e.g. adenine
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Urology & Nephrology (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Vascular Medicine (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US1415807P | 2007-12-17 | 2007-12-17 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200942549A true TW200942549A (en) | 2009-10-16 |
Family
ID=40754075
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW097148847A TW200942549A (en) | 2007-12-17 | 2008-12-16 | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
Country Status (10)
Country | Link |
---|---|
US (4) | US8288397B2 (zh) |
EP (1) | EP2224929B1 (zh) |
JP (1) | JP5562865B2 (zh) |
AR (1) | AR069777A1 (zh) |
CL (1) | CL2008003749A1 (zh) |
PA (1) | PA8808201A1 (zh) |
PE (1) | PE20091102A1 (zh) |
TW (1) | TW200942549A (zh) |
UY (1) | UY31540A1 (zh) |
WO (1) | WO2009078999A1 (zh) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8288397B2 (en) | 2007-12-17 | 2012-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
JP6081797B2 (ja) * | 2009-07-07 | 2017-02-15 | バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツングBayer Intellectual Property GmbH | (2,4−ジメチルビフェニル−3−イル)酢酸、それらのエステルおよび中間体を調製する方法 |
WO2011078143A1 (ja) * | 2009-12-22 | 2011-06-30 | 塩野義製薬株式会社 | ピリミジン誘導体およびそれらを含有する医薬組成物 |
WO2012078909A1 (en) * | 2010-12-08 | 2012-06-14 | Proteostasis Therapeutics, Inc. | Thiazolpyrimidine proteostasis regulators |
CA2873975A1 (en) | 2012-05-21 | 2013-11-28 | Bayer Pharma Aktiengesellschaft | Thienopyrimidines |
JP2016512491A (ja) * | 2013-03-06 | 2016-04-28 | バイエル・ファルマ・アクティエンゲゼルシャフト | 置換チアゾロピリミジン類 |
RU2016110852A (ru) | 2013-09-27 | 2017-10-30 | Нимбус Айрис, Инк. | Ингибиторы irak и их применения |
AR104020A1 (es) * | 2015-06-04 | 2017-06-21 | Kura Oncology Inc | Métodos y composiciones para inhibir la interacción de menina con proteínas mill |
IT201600070952A1 (it) * | 2016-07-07 | 2018-01-07 | Univ Degli Studi Di Ferrara | NUOVI TIAZOLO[5,4-d]PIRIMIDIN DERIVATI QUALI AGONISTI INVERSI DEI RECETTORI A2A DELL’ADENOSINA |
CA3106692A1 (en) * | 2017-07-19 | 2019-01-24 | Aazeintx Inc. | Method to abate acute airway hypersensitivity and asthma attacks |
GB201811169D0 (en) * | 2018-07-06 | 2018-08-29 | Kancera Ab | New compounds |
WO2021102330A1 (en) * | 2019-11-21 | 2021-05-27 | Synventa Llc | Compositions and methods for treatment of pain |
Family Cites Families (121)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4160834A (en) | 1977-03-09 | 1979-07-10 | Eli Lilly And Company | 1-(Substituted benzoyl)-3-(substituted pyrazinyl)ureas |
JPH03167178A (ja) | 1989-11-24 | 1991-07-19 | Taiji Nakayama | ピリミジン誘導体 |
JPH03255077A (ja) | 1990-03-01 | 1991-11-13 | Taiji Nakayama | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
SE468719B (sv) | 1991-07-02 | 1993-03-08 | Saab Scania Ab | Arrangemang foer braensleledning vid foerbraenningsmotor |
AU3427093A (en) | 1992-01-15 | 1993-08-03 | E.I. Du Pont De Nemours And Company | Bridged heterocyclic fungicides |
JPH06172355A (ja) | 1992-04-14 | 1994-06-21 | Mect Corp | ピリミジン誘導体およびそれを有効成分とする血小板凝集阻止剤 |
JPH0625243A (ja) | 1992-07-08 | 1994-02-01 | Sankyo Co Ltd | 1−メチルカルバペネム誘導体の製造法 |
DE4332168A1 (de) | 1993-02-22 | 1995-03-23 | Thomae Gmbh Dr K | Cyclische Derivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
DE19624069A1 (de) | 1996-06-17 | 1997-12-18 | Thomae Gmbh Dr K | Benzazepinderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung |
US6150343A (en) | 1993-06-30 | 2000-11-21 | University Of Pittsburgh | Camptothecin analogs and methods of preparation thereof |
US5512563A (en) | 1993-07-29 | 1996-04-30 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5834461A (en) | 1993-07-29 | 1998-11-10 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
US5428040A (en) | 1993-08-31 | 1995-06-27 | The Du Pont Merck Pharmaceutical Company | Carbocyclic fused-ring quinolinecarboxylic acids useful as immunosuppressive agents |
AR002459A1 (es) | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
AR004010A1 (es) | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
US5985799A (en) | 1995-11-17 | 1999-11-16 | E.I. Du Pont De Nemours And Company | Tricyclic herbicidal heterocycles |
US6107300A (en) | 1996-03-27 | 2000-08-22 | Dupont Pharmaceuticals | Arylamino fused pyrimidines |
JP3531169B2 (ja) | 1996-06-11 | 2004-05-24 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
AU3296497A (en) | 1996-06-13 | 1998-01-07 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
EP0973778A1 (en) | 1997-03-07 | 2000-01-26 | Novo Nordisk A/S | 4,5,6,7-TETRAHYDRO-THIENO 3,2-c]PYRIDINE DERIVATIVES, THEIR PREPARATION AND USE |
ZA982368B (en) | 1997-03-27 | 1998-09-23 | Akzo Nobel Nv | New therapeutic combinations |
AU7445498A (en) | 1997-06-25 | 1999-01-04 | Pfizer Inc. | Dipeptide derivatives as growth hormone secretagogues |
US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
US6358951B1 (en) | 1998-08-21 | 2002-03-19 | Pfizer Inc. | Growth hormone secretagogues |
CZ27399A3 (cs) | 1999-01-26 | 2000-08-16 | Ústav Experimentální Botaniky Av Čr | Substituované dusíkaté heterocyklické deriváty, způsob jejich přípravy, tyto deriváty pro použití jako léčiva, farmaceutická kompozice a kombinovaný farmaceutický přípravek tyto deriváty obsahující a použití těchto derivátů pro výrobu léčiv |
JP2001097979A (ja) | 1999-07-28 | 2001-04-10 | Takeda Chem Ind Ltd | 縮合複素環化合物、その製造法および用途 |
US7160890B2 (en) * | 1999-12-02 | 2007-01-09 | Osi Pharmaceuticals, Inc. | Compounds specific to adenosine A3 receptor and uses thereof |
JP2001294572A (ja) | 2000-02-09 | 2001-10-23 | Dai Ichi Seiyaku Co Ltd | 新規スルホニル誘導体 |
EP1149583A3 (en) | 2000-04-13 | 2001-11-14 | Pfizer Products Inc. | Combinations of corticotropin releasing factor antagonists and growth hormone secretagogues |
DOP2001000154A (es) | 2000-05-25 | 2002-05-15 | Pfizer Prod Inc | Combinación de secretagogos de hormona del crecimiento y antidepresivos |
DE60140285D1 (de) | 2000-05-31 | 2009-12-10 | Pfizer Prod Inc | Verwendung von Wachstumshormonsekretagoga zur Förderung der Beweglichkeit des Verdauungstrakts |
IL143690A0 (en) | 2000-06-19 | 2002-04-21 | Pfizer Prod Inc | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease |
AP2001002196A0 (en) | 2000-06-28 | 2002-12-21 | Pfizer Prod Inc | Melanocortin receptor ligands. |
EP1181933A3 (en) | 2000-06-29 | 2002-04-10 | Pfizer Products Inc. | Use of growth hormone secretagogues for stimulating or increasing appetite |
IL143942A0 (en) | 2000-06-29 | 2002-04-21 | Pfizer Prod Inc | Use of growth hormone secretagogues for treatment of physical performance decline |
US6846813B2 (en) | 2000-06-30 | 2005-01-25 | Pharmacia & Upjohn Company | Compounds to treat alzheimer's disease |
ATE302751T1 (de) | 2000-06-30 | 2005-09-15 | Elan Pharm Inc | Verbindungen zur behandlung der alzheimerischen krankheit |
US6369222B1 (en) | 2000-07-18 | 2002-04-09 | Hoffmann-La Roche Inc. | mGluR antagonists and a method for their synthesis |
IL144468A0 (en) | 2000-07-27 | 2002-05-23 | Pfizer Prod Inc | Use of growth hormone secretagogues for improvement of functional health status |
US6660731B2 (en) | 2000-09-15 | 2003-12-09 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
MXPA03002294A (es) | 2000-09-15 | 2005-09-08 | Vertex Pharma | Compuestos de pirazol utiles como inhibidores de proteina cinasa. |
EP1192943A3 (en) | 2000-09-28 | 2002-11-27 | Pfizer Products Inc. | Use of growth hormone secretagogues in conjunction with physical exercise |
HU230302B1 (hu) | 2000-10-20 | 2015-12-28 | Eisai R&D Management Co., Ltd. | Nitrogéntartalmú aromás származékok és ezeket tartalmazó gyógyászati készítmények |
EP1345922B1 (en) | 2000-12-21 | 2006-05-31 | Vertex Pharmaceuticals Incorporated | Pyrazole compounds useful as protein kinase inhibitors |
EP2256104A1 (en) | 2000-12-27 | 2010-12-01 | Merck Patent GmbH | Process for the preparation of alpha-aminosubstituted carboxylic acid amides |
US7105667B2 (en) | 2001-05-01 | 2006-09-12 | Bristol-Myers Squibb Co. | Fused heterocyclic compounds and use thereof |
WO2002088079A2 (en) | 2001-05-01 | 2002-11-07 | Bristol-Myers Squibb Company | Dual inhibitors of pde 7 and pde 4 |
US6686352B2 (en) | 2001-05-18 | 2004-02-03 | Hoffmann-La Roche Inc. | Substituted imidazo [1,5-a] pyrimido [5,4-d] [1] benzazepine derivatives |
EP2336133A1 (en) * | 2001-10-30 | 2011-06-22 | Conforma Therapeutics Corporation | Purine analogs having HSP90-inhibiting activity |
EP1448565B1 (en) | 2001-11-30 | 2009-12-30 | Schering Corporation | ADENOSINE A2a RECEPTOR ANTAGONISTS |
CN1627944A (zh) | 2002-01-17 | 2005-06-15 | 神经能质公司 | 取代的喹唑啉-4-基胺类似物作为辣椒辣素调节剂 |
JP2003321472A (ja) | 2002-02-26 | 2003-11-11 | Takeda Chem Ind Ltd | Grk阻害剤 |
US20030199514A1 (en) | 2002-03-27 | 2003-10-23 | Fryburg David A. | Methods for improving efficacy of treatment with growth hormone secretagogues |
EP1552842A1 (en) | 2002-06-07 | 2005-07-13 | Kyowa Hakko Kogyo Co., Ltd. | Bicyclic pyrimidine derivatives |
JP2005535631A (ja) * | 2002-06-27 | 2005-11-24 | エフ.ホフマン−ラ ロシュ アーゲー | プリン誘導体の合成 |
US20030139427A1 (en) * | 2002-08-23 | 2003-07-24 | Osi Pharmaceuticals Inc. | Bicyclic pyrimidinyl derivatives and methods of use thereof |
GB0221828D0 (en) | 2002-09-20 | 2002-10-30 | Astrazeneca Ab | Novel compound |
WO2004043367A2 (en) | 2002-11-06 | 2004-05-27 | Bristol-Myers Squibb Company | Fused heterocyclic compounds and use thereof |
JP2006517234A (ja) | 2003-02-10 | 2006-07-20 | アムジエン・インコーポレーテツド | バニロイド受容体リガンドおよび治療におけるこれらのリガンドの使用 |
US20040157645A1 (en) * | 2003-02-12 | 2004-08-12 | Smith Adrian David | System and method of operation an array antenna in a distributed wireless communication network |
AR045979A1 (es) * | 2003-04-28 | 2005-11-23 | Astrazeneca Ab | Amidas heterociclicas |
WO2004108120A1 (en) | 2003-06-11 | 2004-12-16 | Pfizer Products Inc. | Use of growth hormone secretagogues for treatment of fibromyalgia |
DE602004023299D1 (de) | 2003-07-21 | 2009-11-05 | Pfizer Prod Inc | Nikotin abhängigkeit reduzierende heteroaryl kondensierte azapolycyclische verbindungen |
KR20060118398A (ko) | 2003-08-05 | 2006-11-23 | 버텍스 파마슈티칼스 인코포레이티드 | 전압 개폐 이온 채널 억제제로서의 축합 피라미딘 화합물 |
WO2005014548A1 (ja) | 2003-08-08 | 2005-02-17 | Sumitomo Chemical Company, Limited | ジソピラミド遊離塩基の低融点型結晶の製造方法 |
US20070105865A1 (en) | 2003-09-09 | 2007-05-10 | Neurogen Corporation | Substituted bicyclic quinazolin-4-ylamine derivatives |
CA2540640A1 (en) | 2003-09-30 | 2005-04-14 | Amgen Inc. | Vanilloid receptor ligands and their use in treatments |
JP2007507494A (ja) * | 2003-10-07 | 2007-03-29 | アストラゼネカ・アクチエボラーグ | ケモカイン受容体アンタゴニストとりわけCX3CR1として有用な新規な2−置換4−アミノ−チアゾロ[4,5−d]ピリミジン |
CA2545725A1 (en) | 2003-11-14 | 2005-06-02 | Merck Sharp & Dohme Limited | Bicyclic pyrimidin-4-(3h)-ones and analogues and derivatives thereof which modulate the function of the vanilloid-1 receptor (vr1) |
US7816356B2 (en) | 2003-11-14 | 2010-10-19 | Daniel Yohannes | Aryl and heteroaryltetrahydrocyclobutapyrroles as nicotinic acetylcholine receptor ligands |
JP2005162673A (ja) | 2003-12-03 | 2005-06-23 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体 |
US7312330B2 (en) | 2003-12-24 | 2007-12-25 | Renovis, Inc. | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
TW200530235A (en) | 2003-12-24 | 2005-09-16 | Renovis Inc | Bicycloheteroarylamine compounds as ion channel ligands and uses thereof |
MXPA06008257A (es) | 2004-01-23 | 2006-08-31 | Amgen Inc | Ligandos del receptor vanilloide y su uso en tratamientos. |
WO2005082865A1 (ja) | 2004-02-27 | 2005-09-09 | Astellas Pharma Inc. | 縮合二環性ピリミジン誘導体 |
EP1731523A4 (en) | 2004-04-01 | 2009-08-12 | Takeda Pharmaceutical | THIAZOLOPYRIMIDINE DERIVATIVE |
GB0412467D0 (en) | 2004-06-04 | 2004-07-07 | Astrazeneca Ab | Chemical compounds |
ITMI20041231A1 (it) | 2004-06-18 | 2004-09-18 | Pharmeste Srl | Antagonisti del recettore dei vanilloidi trpv1 |
ITMI20041566A1 (it) | 2004-07-30 | 2004-10-30 | Indena Spa | "trpv1 agonisti, formulazioni che li contengono e loro usi" |
FR2874015B1 (fr) | 2004-08-05 | 2006-09-15 | Sanofi Synthelabo | Derives de n-(1h-indolyl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique |
JP2006083085A (ja) | 2004-09-15 | 2006-03-30 | Kyowa Hakko Kogyo Co Ltd | 二環性ピリミジン誘導体の製造法およびその合成中間体 |
GB0420719D0 (en) | 2004-09-17 | 2004-10-20 | Addex Pharmaceuticals Sa | Novel allosteric modulators |
EP1799684B1 (en) | 2004-10-04 | 2014-12-03 | Millennium Pharmaceuticals, Inc. | Lactam compounds useful as protein kinase inhibitors |
WO2006044762A2 (en) | 2004-10-15 | 2006-04-27 | Bayer Pharmaceuticals Corporation | Tetrahydro-5h-pyrimido[4,5-d]azepine derivatives useful for the treatment of diseases associated with the 5-ht2c receptor |
JP4932730B2 (ja) | 2004-11-24 | 2012-05-16 | アボット・ラボラトリーズ | バニロイド受容体サブタイプ1(vr1)受容体を阻害するクロマニル尿素化合物およびその使用 |
US7725934B2 (en) | 2004-12-07 | 2010-05-25 | Cisco Technology, Inc. | Network and application attack protection based on application layer message inspection |
US20060128710A1 (en) | 2004-12-09 | 2006-06-15 | Chih-Hung Lee | Antagonists to the vanilloid receptor subtype 1 (VR1) and uses thereof |
US7521446B2 (en) | 2005-01-13 | 2009-04-21 | Signal Pharmaceuticals, Llc | Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith |
CN101232885A (zh) | 2005-01-25 | 2008-07-30 | 神经能质公司 | 经取代的哒嗪基喹啉-4-基胺和嘧啶基喹啉-4-基胺类似物 |
JP2008540633A (ja) | 2005-05-18 | 2008-11-20 | ファイザー・リミテッド | バソプレッシン拮抗薬としての1,2,4−トリアゾール誘導体 |
WO2006130469A1 (en) | 2005-05-27 | 2006-12-07 | Oregon Health & Science University | Stimulation of neurite outgrowth by small molecules |
PE20070171A1 (es) | 2005-06-30 | 2007-03-08 | Boehringer Ingelheim Int | GLICINAMIDAS SUSTITUIDAS CON EFECTO ANTITROMBOTICO E INHIBIDOR DEL FACTOR Xa |
US20070032473A1 (en) | 2005-07-19 | 2007-02-08 | Kai Gerlach | Substituted amides and their use as medicaments |
KR20080097382A (ko) | 2005-07-21 | 2008-11-05 | 뉴사우스 이노베이션즈 피티와이 리미티드 | 암의 치료 방법 |
ATE539753T1 (de) | 2005-08-04 | 2012-01-15 | Janssen Pharmaceutica Nv | Pyrimidin-verbindungen als serotonin-rezeptor- modulatoren |
US7598255B2 (en) | 2005-08-04 | 2009-10-06 | Janssen Pharmaceutica Nv | Pyrimidine compounds as serotonin receptor modulators |
EP1912639A4 (en) * | 2005-08-08 | 2011-10-12 | Janssen Pharmaceutica Nv | Thiazolopyrimidine KINASE INHIBITORS |
WO2007047798A1 (en) | 2005-10-21 | 2007-04-26 | Sensis Corporation | Method and apparatus for providing secure access control for protected information |
BRPI0618900A2 (pt) | 2005-11-22 | 2011-09-27 | Smithkline Beecham Corp | compostos calcilìticos |
JP4678685B2 (ja) | 2005-12-26 | 2011-04-27 | 株式会社吉野工業所 | エアゾール式液噴出器 |
DE102005062987A1 (de) | 2005-12-28 | 2007-07-05 | Grünenthal GmbH | Substituierte Propiolsäureamide und ihre Verwendung zur Herstellung von Arzneimitteln |
US20070155747A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Inhibitors of fatty acid amide hydrolase |
US20070155707A1 (en) | 2005-12-29 | 2007-07-05 | Kadmus Pharmaceuticals, Inc. | Ionizable inhibitors of fatty acid amide hydrolase |
BRPI0706610A2 (pt) | 2006-01-18 | 2011-04-05 | Siena Biotech Spa | moduladores de receptores alfa 7 nicotìnico acetilcolina e usos terapêuticos destes |
EP1818330A1 (de) | 2006-02-14 | 2007-08-15 | Boehringer Ingelheim Pharma GmbH & Co.KG | Substituierte Prolinamide, deren Herstellung und deren Verwendung als Arzneimittel |
AU2007225273A1 (en) | 2006-03-10 | 2007-09-20 | Neurogen Corporation | Piperazinyl oxoalkyl tetrahydroisoquinolines and related analogues |
BRPI0709035A2 (pt) | 2006-03-21 | 2011-06-21 | Schering Corp | compostos de piridina substituìda heterocìclica com atividade antagonista de cxcr3 |
PE20080145A1 (es) | 2006-03-21 | 2008-02-11 | Janssen Pharmaceutica Nv | Tetrahidro-pirimidoazepinas como moduladores de trpv1 |
US7951829B2 (en) * | 2006-05-03 | 2011-05-31 | Janssen Pharmaceutica Nv | Benzimidazole modulators of VR1 |
JP5167250B2 (ja) | 2006-05-16 | 2013-03-21 | メルク・シャープ・エンド・ドーム・コーポレイション | 糖尿病の治療又は予防のためのジペプチジルペプチダーゼiv阻害剤としてのアミノテトラヒドロピラン |
ATE481409T1 (de) * | 2006-05-18 | 2010-10-15 | Hoffmann La Roche | Thiazolopyramidin/pyridinharnstoffderivate als antagonisten am adenosin-a2b-rezeptor |
US20080051387A1 (en) | 2006-06-09 | 2008-02-28 | Yuelian Xu | Tetrahydropyrido[3,4-d]pyrimidines and related analogues |
TWI367112B (en) | 2006-06-30 | 2012-07-01 | Schering Corp | Immediate-release tablet formulations of a thrombin receptor antagonist |
US20080004286A1 (en) | 2006-06-30 | 2008-01-03 | Schering Corporation | Method of Using Substituted Piperidines that Increase P53 Activity |
WO2008005303A2 (en) | 2006-06-30 | 2008-01-10 | Janssen Pharmaceutica N.V. | Thiazolopyrimidine modulators of trpv1 |
BRPI0713119A2 (pt) | 2006-06-30 | 2012-04-17 | Schering Corp | piperidinas substituìdas que aumentam a atividade de p53 e os usos destas |
WO2008024139A2 (en) | 2006-08-18 | 2008-02-28 | N.V. Organon | Inhibitors of fatty acid amide hydrolase |
CA2661223A1 (en) | 2006-08-22 | 2008-02-28 | Concert Pharmaceuticals Inc. | 4-aminoquinazoline derivatives and methods of use thereof |
JP2009007273A (ja) | 2007-06-27 | 2009-01-15 | Ajinomoto Co Inc | ジアミノピリミジン化合物の製造方法 |
US8288397B2 (en) | 2007-12-17 | 2012-10-16 | Janssen Pharmaceutica Nv | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 |
WO2009079000A1 (en) | 2007-12-17 | 2009-06-25 | Janssen Pharmaceutica N.V. | Imidazolopyrimidine modulators of trpv1 |
-
2008
- 2008-12-16 US US12/316,848 patent/US8288397B2/en active Active
- 2008-12-16 JP JP2010539471A patent/JP5562865B2/ja active Active
- 2008-12-16 EP EP08862830.0A patent/EP2224929B1/en active Active
- 2008-12-16 PE PE2008002082A patent/PE20091102A1/es not_active Application Discontinuation
- 2008-12-16 WO PCT/US2008/013808 patent/WO2009078999A1/en active Application Filing
- 2008-12-16 CL CL2008003749A patent/CL2008003749A1/es unknown
- 2008-12-16 TW TW097148847A patent/TW200942549A/zh unknown
- 2008-12-17 UY UY31540A patent/UY31540A1/es unknown
- 2008-12-17 PA PA20088808201A patent/PA8808201A1/es unknown
- 2008-12-17 AR ARP080105488A patent/AR069777A1/es unknown
-
2012
- 2012-09-12 US US13/611,936 patent/US8637527B2/en active Active
-
2013
- 2013-12-19 US US14/133,848 patent/US9440978B2/en active Active
-
2016
- 2016-09-12 US US15/262,202 patent/US20160376291A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP2224929B1 (en) | 2016-05-04 |
JP5562865B2 (ja) | 2014-07-30 |
UY31540A1 (es) | 2009-07-17 |
AR069777A1 (es) | 2010-02-17 |
WO2009078999A1 (en) | 2009-06-25 |
JP2011506608A (ja) | 2011-03-03 |
US8637527B2 (en) | 2014-01-28 |
US8288397B2 (en) | 2012-10-16 |
US20090156599A1 (en) | 2009-06-18 |
PE20091102A1 (es) | 2009-07-25 |
EP2224929A1 (en) | 2010-09-08 |
US20160376291A1 (en) | 2016-12-29 |
EP2224929A4 (en) | 2011-08-03 |
US9440978B2 (en) | 2016-09-13 |
US20140107098A1 (en) | 2014-04-17 |
US20130005687A1 (en) | 2013-01-03 |
PA8808201A1 (es) | 2010-05-26 |
CL2008003749A1 (es) | 2010-01-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008005303A3 (en) | Thiazolopyrimidine modulators of trpv1 | |
TW200942549A (en) | Imidazolo-, oxazolo-, and thiazolopyrimidine modulators of TRPV1 | |
UA92636C2 (en) | Tetrahydro-pyrimidoazepines as modulators of trpv1 | |
HUS2100051I1 (hu) | Kompozíciók és eljárások sejtproliferációs rendellenességek kezelésére | |
MX2009008787A (es) | Moduladores 2-aminopirimidina del receptor de histamina h4. | |
TN2010000122A1 (en) | Compounds and compositions as modulators of gpr119 activity | |
MX2009009491A (es) | Compuestos y composiciones como moduladores de la actividad del gpr119. | |
AU2012253759A8 (en) | Tricyclic sulfonamide compounds and methods of making and using same | |
WO2006124748A3 (en) | Multicyclic compounds and methods of their use | |
AU2012253757A8 (en) | Partially saturated tricyclic compounds and methods of making and using same | |
TW200714590A (en) | Heterocyclic inhibitors of MEK and methods of use thereof | |
CY1109985T1 (el) | Αναστολεις πρωτεασωματος και μεθοδοι χρησης αυτων | |
MX2007009356A (es) | Compuestos y composiciones como moduladores de ppar. | |
TW200716091A (en) | New therapeutic combinations for the treatment or prevention of psychotic disorders | |
TNSN08370A1 (en) | Tetrahydropyridothienopyrimidine compounds and methods of use thereof | |
MY144970A (en) | Heterocyclic compounds | |
DE602007010764D1 (en) | Benzamidglucokinaseaktivatoren | |
BR112014027981A2 (pt) | compostos do tipo fumagilol e métodos de produção e utilização dos mesmos | |
MX2012004078A (es) | Compuestos y composiciones como moduladores de la actividad de gpr119. | |
MX2009008425A (es) | Derivados de 1-bencensulfonil-1h-indol como inhibidores de la actividad de ccr9. | |
WO2008100618A3 (en) | Carbon-linked tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
WO2008100621A3 (en) | Tetrahydro-pyrazolo-pyridine thioether modulators of cathepsin s | |
MX2013002118A (es) | 2-oxi-quinolin-3-carboxamidas sustituidas como moduladores de kcnq2/3. | |
WO2008100620A3 (en) | Bicyclic aminopropyl tetrahydro-pyrazolo-pyridine modulators of cathepsin s | |
WO2006079068A3 (en) | Compositions and methods for studying and treating inflammatory diseases and disorders |